Recognizing the value of the discovery and validation of new pharmaceutical targets would be a major step forward for pharmaceutical policy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
University of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916 (Fed. Cir.), reh'g en banc denied, 375 F.3d 1303, cert. denied, 160 L. Ed. 2d 484 (2004).
The Trilateral Co-operation. Mutual understanding in search and examination: comparative study on biotechnology patent practices (Trilateral Project B3b) (The Trilateral Co-operation, 2001). http://www.trilateral.net/projects/biotechnology/reach_through_claims/
Avorn, J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (Knopf, New York, 2004).
Marcia Angell. The Truth About the Drug Companies: How They Deceive Us and What To Do About It (Random House, New York, 2004).
American Hospital Formulary Service. Antilipemic agents 24:06, HMG-CoA reductase inhibitors (American Society of Health-System Pharmacists, Bethesda, MD, USA, 2002).
Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry (US Congressional Budget Office, Washington, DC, 1998).
Bohrer, R.A. N. Engl. J. Med. 343, 1416 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bohrer, R. Reach-through claims for drug target patents: Rx for pharmaceutical policy. Nat Biotechnol 26, 55–56 (2008). https://doi.org/10.1038/nbt0108-55
Issue Date:
DOI: https://doi.org/10.1038/nbt0108-55
